Tenaya Therapeutics Inc(TNYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TNYA Tenaya Therapeutics Inc

Market Closed 02-27 16:00:00 EST

0.5618

-0.0473

-7.77%

盘后0.5760

+0.0142+2.53%

19:48 EST

High0.6091	Low0.5618	Vol2.67M
Open0.6090	D1 Closing0.6091	Amplitude7.77%
Mkt Cap121.63M	Tradable Cap115.64M	Total Shares216.51M
T/O1.54M	T/O Rate1.30%	Tradable Shares205.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TNYA","market":"US","secType":"STK","nameCN":"Tenaya Therapeutics Inc","latestPrice":0.5618,"timestamp":1772226000000,"preClose":0.6091,"halted":0,"volume":2665694,"hourTrading":{"tag":"盘后","latestPrice":0.576,"preClose":0.5618,"latestTime":"19:48 EST","volume":44833,"amount":26057.964352,"timestamp":1772239700302,"change":0.0142,"changeRate":0.025276,"amplitude":0.050552},"delay":0,"changeRate":-0.07765555737974061,"floatShares":205841252,"shares":216505900,"eps":-0.75,"marketStatus":"Market Closed","change":-0.0473,"latestTime":"02-27 16:00:00 EST","open":0.609,"high":0.6091,"low":0.5618,"amount":1539146.9246458001,"amplitude":0.077656,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.75,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":0.6091,"preHourTrading":{"tag":"盘前","latestPrice":0.61,"preClose":0.6091,"latestTime":"09:25 EST","volume":3796,"amount":2318.5715566,"timestamp":1772202356743,"change":0.0009,"changeRate":0.001478,"amplitude":0.022821},"postHourTrading":{"tag":"盘后","latestPrice":0.576,"preClose":0.5618,"latestTime":"19:48 EST","volume":44833,"amount":26057.964352,"timestamp":1772239700302,"change":0.0142,"changeRate":0.025276,"amplitude":0.050552},"volumeRatio":0.6562054015276148,"impliedVol":1.5679,"impliedVolPercentile":0.4861},"requestUrl":"/m/hq/s/TNYA","defaultTab":"news","newsList":[{"id":"2614814236","title":"e.l.f., Crown Castle, DoorDash, Stag, Tenaya Shake-Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2614814236","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614814236?lang=en_us&edition=fundamental","pubTime":"2026-02-28 21:01","pubTimestamp":1772283682,"startTime":"0","endTime":"0","summary":"Insiders have been trading these 5 stocks: (($ELF)), (($CCI)), (($DASH)), (($STAG)) and (($TNYA)). Here is a breakdown of their recent trades and t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/e-l-f-crown-castle-doordash-stag-tenaya-shake-up?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/e-l-f-crown-castle-doordash-stag-tenaya-shake-up?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","LU0353189680.USD","BK4139","BK4535","BK4209","BK4084","DASX","BK4548","BK4549","LU2065169927.USD","BK4219","BK4503","BK4539","BK4588","DASH","LU2065171402.SGD","LU2087625088.SGD","LU0353189763.USD","LU2065171311.SGD","BK4515","BK4585","LU2065170008.USD","TNYA","BK4566","BK4505","BK4122","CCI","BK4536","LU0786609619.USD"],"gpt_icon":0},{"id":"2614678448","title":"Tenaya Therapeutics Inc  expected to post a loss of 12 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2614678448","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614678448?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:26","pubTimestamp":1772227567,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc  expected to post a loss of12cents a share - Earnings Preview Tenaya Therapeutics Inc TNYA.OQ TNYA.O is expected to  show no change in quarterly revenue when it reports  result","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL8N3ZN2R7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TNYA","BK4539"],"gpt_icon":0},{"id":"2614079777","title":"Column Group III GP, LP Disposes of Tenaya Therapeutics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2614079777","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614079777?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:34","pubTimestamp":1772141696,"startTime":"0","endTime":"0","summary":"The Column Group III GP, LP reported a disposal of common shares of Tenaya Therapeutics, Inc. Other reporting beneficial owners included The Column Group III, LP, The Column Group III-A, LP, Column Group Opportunity III, LP, and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL9mSzjb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Column Group III GP, LP Disposes of Tenaya Therapeutics Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TNYA","BK4539"],"gpt_icon":0},{"id":"2614651728","title":"Column Group III GP, LP reports disposal of Tenaya Therapeutics common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2614651728","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614651728?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:13","pubTimestamp":1771967636,"startTime":"0","endTime":"0","summary":"The Column Group III GP, LP, a 10% owner of Tenaya Therapeutics, Inc. , reported a disposal of the company’s common shares. The Form 4 was filed by more than one reporting person, including The Column Group III, LP, The Column Group III-A, LP, and Tim Kutzkey, along with other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL9xHYZh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Column Group III GP, LP reports disposal of Tenaya Therapeutics common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","TNYA"],"gpt_icon":0},{"id":"2611818864","title":"Major Tenaya Therapeutics Stake Dumped by Key Shareholder in Eye‑Catching Move","url":"https://stock-news.laohu8.com/highlight/detail?id=2611818864","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611818864?lang=en_us&edition=fundamental","pubTime":"2026-02-13 10:05","pubTimestamp":1770948331,"startTime":"0","endTime":"0","summary":"New insider activity at Tenaya Therapeutics ( ($TNYA) ) has taken place on February 12, 2026. Significant shareholder COLUMN GROUP III GP, LP has o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-tenaya-therapeutics-stake-dumped-by-key-shareholder-in-eye‑catching-move-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-tenaya-therapeutics-stake-dumped-by-key-shareholder-in-eye‑catching-move-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNYA","BK4539","BK4139"],"gpt_icon":0},{"id":"2611290594","title":"Column Group III GP, LP Reports Disposal of Tenaya Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611290594","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611290594?lang=en_us&edition=fundamental","pubTime":"2026-02-13 06:19","pubTimestamp":1770934785,"startTime":"0","endTime":"0","summary":"Column Group III GP, LP, a 10% owner, reported a disposal of common shares of Tenaya Therapeutics Inc. Other reporting beneficial owners include Column Group III, LP and Column Group III-A, LP. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL577SLr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Column Group III GP, LP Reports Disposal of Tenaya Therapeutics Inc. Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TNYA","BK4139"],"gpt_icon":0},{"id":"2607202223","title":"Tenaya Therapeutics Faces Nasdaq Deficiency, Amends Equity Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2607202223","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607202223?lang=en_us&edition=fundamental","pubTime":"2026-01-31 06:30","pubTimestamp":1769812220,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics ( ($TNYA) ) has issued an update. On January 28, 2026, Tenaya Therapeutics disclosed that it had received a deficiency notice f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tenaya-therapeutics-faces-nasdaq-deficiency-amends-equity-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tenaya-therapeutics-faces-nasdaq-deficiency-amends-equity-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NQmain","EQR","TNYA","BK4588","BK4539","BK4215","BK4585"],"gpt_icon":0},{"id":"2605414022","title":"Tenaya Therapeutics (TNYA) Valuation After 2026 Gene Therapy Updates And US$60 Million Capital Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2605414022","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605414022?lang=en_us&edition=fundamental","pubTime":"2026-01-23 02:34","pubTimestamp":1769106859,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics (TNYA) is back in focus after updating investors on its heart disease gene therapy programs, outlining 2026 clinical milestones alongside a recent US$60 million capital raise that extends its cash runway.\nSee our latest analysis for Tenaya Therapeutics.\nAt a recent share price of US$0.72, Tenaya’s 1 day share price return of 1.95% follows a 90 day share price return decline of 57.39% and a 1 year total shareholder return decline of 44.07%. This suggests that near term...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnya/tenaya-therapeutics/news/tenaya-therapeutics-tnya-valuation-after-2026-gene-therapy-u","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnya/tenaya-therapeutics/news/tenaya-therapeutics-tnya-valuation-after-2026-gene-therapy-u","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TNYA","BK4539"],"gpt_icon":0},{"id":"2602230886","title":"Tenaya Therapeutics: 2026 Clinical Milestones, FDA Pivotal Pathway, and Strengthened Balance Sheet Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2602230886","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602230886?lang=en_us&edition=fundamental","pubTime":"2026-01-10 00:35","pubTimestamp":1767976537,"startTime":"0","endTime":"0","summary":"William Blair analyst Sami Corwin has maintained their bullish stance on TNYA stock, giving a Buy rating today. Sami Corwin has given his Buy ratin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tenaya-therapeutics-2026-clinical-milestones-fda-pivotal-pathway-and-strengthened-balance-sheet-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tenaya-therapeutics-2026-clinical-milestones-fda-pivotal-pathway-and-strengthened-balance-sheet-support-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNYA"],"gpt_icon":0},{"id":"2602370165","title":"Tenaya Therapeutics: 2026 as a Pivotal Year for TN-201 and TN-401 Clinical Readouts and Regulatory De-Risking Supporting a Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2602370165","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602370165?lang=en_us&edition=fundamental","pubTime":"2026-01-10 00:16","pubTimestamp":1767975376,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics today and set a price target of $3.00. Joseph Pantginis has...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tenaya-therapeutics-2026-as-a-pivotal-year-for-tn-201-and-tn-401-clinical-readouts-and-regulatory-de-risking-supporting-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tenaya-therapeutics-2026-as-a-pivotal-year-for-tn-201-and-tn-401-clinical-readouts-and-regulatory-de-risking-supporting-a-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNYA"],"gpt_icon":0},{"id":"2602715243","title":"BRIEF-Tenaya Therapeutics Announces 2026 Strategic Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2602715243","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602715243?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:01","pubTimestamp":1767967317,"startTime":"0","endTime":"0","summary":"BRIEF-Tenaya Therapeutics Announces 2026 Strategic Priorities Jan 9 (Reuters) - Tenaya Therapeutics Inc TNYA.O:TENAYA THERAPEUTICS ANNOUNCES 2026 STRATEGIC PRIORITIES AND ANTICIPATED MILESTONESTENAYA ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA9Y8BSS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","TNYA"],"gpt_icon":0},{"id":"2602237609","title":"Tenaya Therapeutics Outlines 2026 Strategy Including Regulatory Alignment for Gene Therapy Programs, Key Clinical Data Milestones, and Extended Funding Through Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2602237609","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602237609?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965423,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Outlines 2026 Strategy Including Regulatory Alignment for Gene Therapy Programs, Key Clinical Data Milestones, and Extended Funding Through Mid-2027. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDLRQrYh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210149790.SGD","LU2095319765.USD","SG9999014039.USD","SG9999014005.SGD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014021.USD","LU2210150020.SGD","BK4585","TNYA","BK4539","BK4112","NDAQ","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2602937986","title":"Tenaya Therapeutics Inc - Plans to Pursue Regulatory Alignment on Tn-201 in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602937986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602937986?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA9Y8BSS:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TNYA","BK4539"],"gpt_icon":0},{"id":"2602798573","title":"Tenaya Therapeutics Inc - Plans to Pursue Regulatory Alignment on Tn-401 in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602798573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602798573?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA9Y8BSS:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TNYA","BK4539","BK4139"],"gpt_icon":0},{"id":"2602089376","title":"Tenaya Therapeutics Inc - Raised $60 Mln in 4Q25 to Support Runway Through Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2602089376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602089376?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA9Y8BSS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TNYA","BK4139","BK4539"],"gpt_icon":0},{"id":"2602002376","title":"Tenaya Therapeutics - Expects to Report One-Year Cohort 1 Data & Early Cohort 2 Data From Ridge-1 Study of Tn-401 for Pkp2-Associated Arvc in H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602002376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602002376?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA9Y8BSS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TNYA","BK4539"],"gpt_icon":0},{"id":"2602795543","title":"Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602795543","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602795543?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:30","pubTimestamp":1767965400,"startTime":"0","endTime":"0","summary":"Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 withLonger-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK-1 Trial of Adults with MYBPC3-Associated HCM Expects to Repor","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/09/3216081/0/en/Tenaya-Therapeutics-Announces-2026-Strategic-Priorities-and-Anticipated-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4539","BK4139","HCM","BK4531","BK4007","BK4585","TNYA"],"gpt_icon":0},{"id":"2600095819","title":"Tenaya Therapeutics Director David Goeddel Resigns Effective January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2600095819","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600095819?lang=en_us&edition=fundamental","pubTime":"2026-01-03 06:11","pubTimestamp":1767391869,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc. announced that David Goeddel has resigned from its board of directors and all board committees, effective January 26, 2026, following his retirement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDLB0GKk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TNYA","BK4139"],"gpt_icon":0},{"id":"2592618577","title":"Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2592618577","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592618577?lang=en_us&edition=fundamental","pubTime":"2025-12-19 02:36","pubTimestamp":1766082960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TNYA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2025 13:36 ET (18:36 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA"],"gpt_icon":0},{"id":"2591658591","title":"Tenaya Therapeutics (TNYA) Is Down 39.7% After FDA Lifts TN-201 Hold and Trial Updates - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2591658591","media":"Simply Wall St.","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591658591?lang=en_us&edition=fundamental","pubTime":"2025-12-13 23:35","pubTimestamp":1765640158,"startTime":"0","endTime":"0","summary":"Earlier this month, Tenaya Therapeutics reported that the FDA lifted the clinical hold on its MyPEAK-1 Phase 1b/2a trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and released encouraging interim Phase 1b/2 data for TN-401 in arrhythmogenic right ventricular cardiomyopathy, while also completing a US$60,000,000 composite units offering.\nTogether, the resumed TN-201 trial and early TN-401 signals highlight Tenaya’s push to use AAV9-based gene therapies to address inherited...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnya/tenaya-therapeutics/news/tenaya-therapeutics-tnya-is-down-397-after-fda-lifts-tn-201","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnya/tenaya-therapeutics/news/tenaya-therapeutics-tnya-is-down-397-after-fda-lifts-tn-201","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TNYA","BK4539","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tenayatherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0928},{"period":"1month","weight":-0.1488},{"period":"3month","weight":-0.5987},{"period":"6month","weight":-0.5028},{"period":"1year","weight":-0.4382},{"period":"ytd","weight":-0.2104}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.091688},{"month":2,"riseRate":0.2,"avgChangeRate":-0.006231},{"month":3,"riseRate":0.25,"avgChangeRate":-0.154481},{"month":4,"riseRate":0.25,"avgChangeRate":0.087213},{"month":5,"riseRate":0.25,"avgChangeRate":-0.005732},{"month":6,"riseRate":0.25,"avgChangeRate":-0.069846},{"month":7,"riseRate":0.5,"avgChangeRate":-0.023292},{"month":8,"riseRate":0.4,"avgChangeRate":0.09529},{"month":9,"riseRate":0.4,"avgChangeRate":-0.101393},{"month":10,"riseRate":0.2,"avgChangeRate":-0.046678},{"month":11,"riseRate":0.4,"avgChangeRate":0.123533},{"month":12,"riseRate":0.2,"avgChangeRate":-0.128991}],"exchange":"NASDAQ","name":"Tenaya Therapeutics Inc","nameEN":"Tenaya Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tenaya Therapeutics Inc(TNYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tenaya Therapeutics Inc(TNYA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tenaya Therapeutics Inc,TNYA,Tenaya Therapeutics Inc股票,Tenaya Therapeutics Inc股票老虎,Tenaya Therapeutics Inc股票老虎国际,Tenaya Therapeutics Inc行情,Tenaya Therapeutics Inc股票行情,Tenaya Therapeutics Inc股价,Tenaya Therapeutics Inc股市,Tenaya Therapeutics Inc股票价格,Tenaya Therapeutics Inc股票交易,Tenaya Therapeutics Inc股票购买,Tenaya Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tenaya Therapeutics Inc(TNYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tenaya Therapeutics Inc(TNYA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}